TABLE 5

Effects of other drugs on intracranial self-stimulation

Drug PharmacologyaDosesRouteStrain/SpeciesSexICSS ProcedurebDrug EffectcDependent MeasureReference
Drug NameMechanismStructureParameter
mg/kg
NicotinenAChR agonist0.025–0.8s.c.Long Evans ratMaleHybridFrequencyMixed↓θ0Bauco and Wise, 1994
NicotinenAChR agonist0.06–1.0s.c.F-344 ratMaleDiscrete trialAmplitudeFacilitation↓CITHuston-Lyons and Kornetsky, 1992
PentobarbitalGABAA + allosteric modulator2.5–10i.p.Long Evans ratMaleHybridFrequencyFacilitation↓M50Bossert and Franklin, 2003
DiazepamGABAA + allosteric modulator0.5–4.0i.p.C57Bl6/J mouseMaleHybridFrequencyFacilitation↓θ0Straub et al., 2010
Toluene.GABAA + allosteric modulator/NMDA ant480–5000 ppmC57Bl6/J mouseMaleHybridFrequencyMixed↓M50 ↑↓rateTracy et al., 2014
PhencyclidineNMDA antagonist0.5–5.0i.p.CDF ratMaleDiscrete trialAmplitudeFacilitation↓CITKornetsky et al., 1979
PhencyclidineNMDA antagonist0.3–5.6i.p.Wistar ratMaleDiscrete trialAmplitudeNo effectBespalov et al., 1999
PhencyclidineNMDA antagonist2.5 and 5.0i.p.Long Evans ratMaleHybridFrequencyMixed↓θ0 ↑↓rateCarlezon and Wise, 1993b
MK801NMDA antagonist0.01–0.3i.p.Lister ratMaleFree operantMixed↑↓rateHerberg and Rose, 1989
MK801NMDA antagonist0.032–0.32i.p.Sprague-Dawley ratMaleHybridFrequencyMixed↑↓rateHillhouse et al., 2014
KetamineNMDA antagonist0.3–100i.p.Lister ratMaleFree operantMixed↑↓rateHerberg and Rose, 1989
KetamineNMDA antagonist3.2–10i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateHillhouse et al., 2014
THCCB1/CB2 agonist1.0i.p.Fischer 344 ratMaleHybridFrequencyNo effectLepore et al., 1996
THCCB1/CB2 agonist1.0i.p.Lewis ratMaleHybridFrequencyFacilitation↓θ0 ↓M50Lepore et al., 1996
THCCB1/CB2 agonist1.0i.p.Sprague-Dawley ratMaleHybridFrequencyFacilitation↓θ0Lepore et al., 1996
THCCB1/CB2 agonist0.1 and 1.0i.p.Sprague-Dawley ratMaleHybridFrequencyMixed↑↓EF36.7Katsidoni et al., 2013
THCCB1/CB2 agonist1.0–10i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateKwilasz and Negus, 2012
Caffeineadenosine antagonist1.0–20i.p.Wistar ratMaleDiscrete trialAmplitudeMixed↑↓CITBespalov et al., 1999
Testosteroneanabolic steroid50 μgSherman ratMaleFree operantFacilitation↑rateCaggiula and Hoebel, 1966
TripelennamineH1 antagonist0.625–20i.p.CDF ratMaleDiscrete trialAmplitudeFacilitation↓CITUnterwald et al., 1984
  • Rate, response rate; CIT, current-intensity threshold; θ0, theta-0 threshold; M50 or EF50, frequency maintaining 50% maximum rate; EF36.7, frequency maintaining 36.7% maximum rate.

  • a Mechanism of action or drug class.

  • b First column indicates structure of experimental session (see text for details). Second column indicates stimulation parameter under manipulation across trials.

  • c Most prominent drug effect on ICSS.